|24th July 2020||Plc Glaxosmithkline||1,260,504||Open or private purchase||$2.25||$2,836,134.00|
|21st July 2020||Plc Glaxosmithkline||361,111||Open or private purchase||$18.00||$6,499,998.00|
|21st July 2020||Plc Glaxosmithkline||1,538,724||Conversion of derivative||$0.00|
|21st July 2020||Plc Glaxosmithkline||348,469||Conversion of derivative||$0.00|
|15th July 2020||Plc Glaxosmithkline||78||Open or private sale||$19.25||$1,501.50|
|15th July 2020||Plc Glaxosmithkline||3,069||Open or private sale||$19.40||$59,543.51|
|14th July 2020||Plc Glaxosmithkline||79,090||Conversion of derivative||$0.00|
|14th July 2020||Plc Glaxosmithkline||1,597||Open or private sale||$19.27||$30,780.58|
|14th July 2020||Plc Glaxosmithkline||525,499||Conversion of derivative||$0.00|
|14th July 2020||Plc Glaxosmithkline||1,712,810||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Bicycle Therapeutics Plc engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display platform to identify bicycles.